Lindus Health raises €‎16.56M in Series A funding round

London-based Lindus Health announced on Wednesday, August 16, that it has secured $18M (€‎16.56M) in a Series A funding round.

The funding came from Spotify-backer Creandum, with additional contributions from PayPal co-founder Peter Thiel, and returning investors firstminute, Seedcamp, Hambro Perks, Amino Collective, Page One Ventures, and Calm/Storm.

Angel investors Nadav Rosenberg, Kaysan Nikkhah, Trevor Martin, Soraya Darabi, Andrej Steinberg, Tom Krüger, and Mithi Thaya also participated in the round.

“With a tech-first, AI-powered, end-to-end offering, Lindus Health is building unparalleled efficiency and quality into what has always been a manual process,” said Fredrik Cassel, general partner at Creandum.

“The potential Lindus has on improving the world’s health is vast, and we are excited to join them on this journey,” adds Cassel.

As part of the funding round, Cassel will join Lindus Health’s board.

Fund utilisation
According to Michael Young, co-founder of Lindus Health, the fresh funding injection will be dedicated to strengthening the company’s technology platform. This enhancement will open up new and revolutionary approaches for conducting clinical trials.

“Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly,” says Young.

As part of Lindus Health’s growth strategy, the company is actively hiring for crucial positions in business development, clinical operations, and operations management.

Overcoming healthcare hurdles
Lindus Health employs a cutting-edge technology platform that guides clinical trials from inception to conclusion, facilitating the swift delivery of treatments.

By expediting this process, the company seeks to extend and enhance the quality of life for individuals grappling with chronic health conditions.

Meri Beckwith, Lindus Health co-founder, says that the outdated clinical trials sector is impeding advancements in healthcare.

“Everyone suffers from the status quo, especially patients, who must wait decades and pay higher prices for new treatments,” he says.

“We’re excited to accelerate the pace and scale of our work with high-growth companies who will be responsible for the next wave of breakthrough treatment.”

Beckwith also mentions that this investment would aid them in realising their vision of establishing a considerably more flexible and productive life sciences sector, benefiting all parties involved. Silicon Canals